Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | TRIO |
| Gene Name: | TRIO |
| Protein Full Name: | Triple functional domain protein |
| Alias: | EC 2.7.11.1; ERBB1; PTPRF interacting protein; PTPRF-interacting protein; Triple functional domain (PTPRF interacting) |
| Mass (Da): | 346900 |
| Number AA: | 3097 |
| UniProt ID: | O75962 |
| Locus ID: | 7204 |
| COSMIC ID: | TRIO |
| Gene location on chromosome: | 5p15.2 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20284 |
| Percent of cancer specimens with mutations: | 2.34 |
| Found in amplified chromosomal regions in human cancers: | in many different cancer types, copy number gains and high-level amplifications of the short arm of chromosome 5 (band 5p) are frequently observed. This suggests the presence of driver genes on 5p involved in malignant progression. Interestingly, the TRIO |
| Normal role description: | TRIO is a RhoGEF for the monomeric g-proteins RhoG, Rac1, and RhoA. It is upregulated in various empirical cancer systems supporting the notion that constituent activation of Rho and Rac pathways facilitates tumour progression |